U.S. Congress (statute) et al., 2003-12-08: The statute sets Medicare Part B drug payment at 106 percent of average sales price (ASP plus 6%) for multiple-source drugs and, at (b)(1)(B), for single-source drugs and biologics. Its source note records that section 1847A was added by Pub. L. 108-173, title III, sec. 303(c)(1), December 8, 2003 (the Medicare Modernization Act).
in the case of a multiple source drug (as defined in subsection (c)(6)(C)), 106 percent of the amount determined under paragraph (3)
Subsection (b)(1)(A)
U.S. Congress (statute) et al., 2003-12-08: The statute sets Medicare Part B drug payment at 106 percent of average sales price (ASP plus 6%) for multiple-source drugs and, at (b)(1)(B), for single-source drugs and biologics. Its source note records that section 1847A was added by Pub. L. 108-173, title III, sec. 303(c)(1), December 8, 2003 (the Medicare Modernization Act). Public law, no funder, no conflicts, no product. The same section also directs the HHS Inspector General to study whether oncology practices can obtain cancer drugs at 106% of ASP (the study delivered as CHE-08). Note the 2022 Inflation Reduction Act overlay: for selected drugs the 106% applies to the maximum fair price, per (b)(1)(B). Study type: regulatory record.
